M
Masao Tanaka
Researcher at Kyushu University
Publications - 1027
Citations - 38301
Masao Tanaka is an academic researcher from Kyushu University. The author has contributed to research in topics: Pancreatic cancer & Pancreas. The author has an hindex of 88, co-authored 977 publications receiving 35258 citations. Previous affiliations of Masao Tanaka include Kaneka Corporation & University of Occupational and Environmental Health Japan.
Papers
More filters
Journal ArticleDOI
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas
Masao Tanaka,Carlos Fernandez-del Castillo,Volkan Adsay,Suresh T. Chari,Massimo Falconi,Jin-Young Jang,Wataru Kimura,Philippe Lévy,Martha B. Pitman,C. Max Schmidt,Michio Shimizu,Christopher L. Wolfgang,Koji Yamaguchi,Kenji Yamao +13 more
TL;DR: The present guidelines include recent information and recommendations based on the current understanding, and highlight issues that remain controversial and areas where further research is required.
Journal ArticleDOI
International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.
Masao Tanaka,Suresh T. Chari,Volkan Adsay,Carlos Fernandez-del Castillo,Massimo Falconi,Michio Shimizu,Koji Yamaguchi,Kenji Yamao,Seiki Matsuno +8 more
TL;DR: Ovarian-type stroma has been proposed as a requisite to distinguish MCN from IPMN, and some other distinct features to characterize IPMN and MCN have been identified, but there remain ambiguities between the two diseases.
Journal ArticleDOI
Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas.
Masao Tanaka,Carlos Fernandez-del Castillo,Terumi Kamisawa,Jin-Young Jang,Philippe Lévy,Takao Ohtsuka,Roberto Salvia,Yasuhiro Shimizu,Minoru Tada,Christopher L. Wolfgang +9 more
TL;DR: The working group has revised the guidelines regarding prediction of invasive carcinoma and high-grade dysplasia, surveillance, and postoperative follow-up of IPMN and includes updated information and recommendations based on the current understanding.
Journal ArticleDOI
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
Hideki Ueno,Tatsuya Ioka,Masafumi Ikeda,Shinichi Ohkawa,Hiroaki Yanagimoto,Narikazu Boku,Akira Fukutomi,Kazuya Sugimori,Hideo Baba,Kenji Yamao,Tomotaka Shimamura,Masayuki Sho,Masayuki Kitano,Ann-Lii Cheng,Kazuhiro Mizumoto,Jen-Shi Chen,Junji Furuse,Akihiro Funakoshi,Takashi Hatori,Taketo Yamaguchi,Shinichi Egawa,Atsushi Sato,Yasuo Ohashi,Takuji Okusaka,Masao Tanaka +24 more
TL;DR: Monotherapy with S-1 demonstrated noninferiority to gemcitabine in overall survival with good tolerability and presents a convenient oral alternative for locally advanced and metastatic pancreatic cancer.
Journal ArticleDOI
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
H. Ueno,T. Kosuge,Yutaka Matsuyama,J. Yamamoto,Akimasa Nakao,Shinichi Egawa,Ryuichiro Doi,Morito Monden,Takashi Hatori,Masao Tanaka,Mitsuo Shimada,K Kanemitsu +11 more
TL;DR: It is suggested that adjuvant gemcitabine contributes to prolonged disease-free survival (DFS) in patients undergoing macroscopically curative resection of pancreatic cancer.